Tyra Biosciences (NASDAQ:TYRA) Shares Down 5.1% – What’s Next?

23 Jan 2026, 19:19 by Danessa Lincoln · The Markets Daily

Tyra Biosciences, Inc. (NASDAQ:TYRA – Get Free Report)’s share price was down 5.1% during mid-day trading on Friday . The company traded as low as $29.40 and last traded at $29.32. Approximately 145,499 shares traded hands during mid-day trading, a decline of 78% from the average daily volume of 670,453 shares. The stock had previously closed at $30.91.

Analyst Ratings Changes

Several research firms recently weighed in on TYRA. Wedbush increased their price objective on shares of Tyra Biosciences from $30.00 to $37.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 16th. Wall Street Zen raised shares of Tyra Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, January 4th. Piper Sandler raised their target price on shares of Tyra Biosciences from $33.00 to $42.00 and gave the stock an “overweight” rating in a report on Friday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $36.00.

View Our Latest Stock Report on Tyra Biosciences

Tyra Biosciences Stock Down 4.0%

The firm has a market capitalization of $1.58 billion, a price-to-earnings ratio of -15.87 and a beta of 1.07. The business has a 50-day moving average of $24.36 and a two-hundred day moving average of $16.63.

Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.50) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.50). Equities analysts predict that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Insider Activity at Tyra Biosciences

In related news, Director Robert J. More sold 10,000 shares of the stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $25.00, for a total transaction of $250,000.00. Following the completion of the sale, the director owned 3,823,425 shares in the company, valued at $95,585,625. This trade represents a 0.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 15.20% of the company’s stock.

Institutional Investors Weigh In On Tyra Biosciences

A number of large investors have recently bought and sold shares of the business. Public Employees Retirement System of Ohio raised its stake in shares of Tyra Biosciences by 34.8% in the third quarter. Public Employees Retirement System of Ohio now owns 24,962 shares of the company’s stock worth $349,000 after acquiring an additional 6,450 shares during the last quarter. HighVista Strategies LLC raised its stake in Tyra Biosciences by 163.6% during the 3rd quarter. HighVista Strategies LLC now owns 65,812 shares of the company’s stock worth $921,000 after buying an additional 40,850 shares during the period. Commodore Capital LP lifted its holdings in shares of Tyra Biosciences by 8.9% during the 3rd quarter. Commodore Capital LP now owns 3,375,000 shares of the company’s stock valued at $47,216,000 after purchasing an additional 275,000 shares in the last quarter. Boothbay Fund Management LLC acquired a new stake in shares of Tyra Biosciences during the third quarter worth $2,612,000. Finally, Ameriprise Financial Inc. raised its stake in shares of Tyra Biosciences by 8.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 87,107 shares of the company’s stock valued at $1,219,000 after purchasing an additional 6,505 shares during the period. 84.14% of the stock is currently owned by institutional investors.

About Tyra Biosciences

(Get Free Report)

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.